HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saukkonen, T. Articles by Dunger, D. B. Search for Related Content PubMed PubMed Citation Articles by Saukkonen, T. Articles by Dunger, D. B. Social Bookmarking                What's this?

Effects of Recombinant Human IGF-I/IGF-Binding Protein-3 Complex on Glucose and Glycerol Metabolism in Type 1 Diabetes

¹ Department of Paediatrics, University of Cambridge, Cambridge, U.K
² Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
³ Department of Diabetes and Endocrinology, Guy’s, King’s and Thomas’ School of Medicine, London, U.K

Address correspondence and reprint requests to David B Dunger, Department of Paediatrics, University of Cambridge, Box 116, Level 8, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, U.K. E-mail: dbd25{at}cam.ac.uk

Abbreviations: IGFBP, IGF-binding protein; rhIGF-I, recombinant human IGF-I; NEFA, nonesterified fatty acid

Recombinant human IGF-I (rhIGF-I) complexed with its natural binding protein IGF-binding protein (IGFBP)-3 (rhIGF-I/IGFBP-3) is a novel formulation that has been shown to improve insulin sensitivity in type 1 diabetes, yet the mechanisms are not clear. We used stable isotopes to investigate the effects of rhIGF-I/IGFBP-3 on glucose and glycerol metabolism in type 1 diabetes. Fifteen subjects (age 13–24 years; 10 males) were studied on three occasions in random order. Each study period lasted for two days, and an injection of either placebo or rhIGF-I/IGFBP-3 (0.1–0.8 mg · kg^–1 · day ^–1) was given subcutaneously at 6:00 P.M. on days 1 and 2. Following the second injection, the subjects were kept euglycemic overnight by a variable rate insulin infusion, followed by a 4-h, two-step (insulin 0.6 and 1.5 mU · kg^–1 · min ^–1) hyperinsulinemic-euglycemic clamp. During the overnight basal steady state, rhIGF-I/IGFBP-3 dose-dependently reduced endogenous glucose production rate (R_a) (P = 0.004), while peripheral glucose uptake (R_d) was not different from placebo. The increase in glucose R_d during hyperinsulinemic clamp was greater following rhIGF-I/IGFBP-3 than placebo, both during the first (P = 0.008) and second step (P = 0.008) of the clamp. No significant differences were found in glycerol R_a, a measure of lipolysis, between rhIGF-I/IGFBP-3 and placebo. In conclusion, rhIGF-I/IGFBP-3 enhances glucose metabolism by controlling both endogenous glucose output and peripheral glucose uptake.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Ekstrom, J. Salemyr, I. Zachrisson, C. Carlsson-Skwirut, E. Ortqvist, and P. Bang Normalization of the IGF-IGFBP Axis by Sustained Nightly Insulinization in Type 1 Diabetes Diabetes Care, June 1, 2007; 30(6): 1357 - 1363. [Abstract] [Full Text] [PDF]